-
- Erica K. Sloan
- Authors' Affiliations: 1UCLA Norman Cousins Center at the Semel Institute for Neuroscience and Human Behavior, Department of Medicine, 2Division of Hematology-Oncology, UCLA School of Medicine, UCLA AIDS Institute, 3Jonsson Comprehensive Cancer Center, 4UCLA Department of Molecular and Medical Pharmacology, and 5UCLA Molecular Biology Institute, Los Angeles, California; and 6Departments of Gynecologic Oncology and Cancer Biology, M.D. Anderson Comprehensive Cancer Center, Houston, Texas
-
- Saul J. Priceman
- Authors' Affiliations: 1UCLA Norman Cousins Center at the Semel Institute for Neuroscience and Human Behavior, Department of Medicine, 2Division of Hematology-Oncology, UCLA School of Medicine, UCLA AIDS Institute, 3Jonsson Comprehensive Cancer Center, 4UCLA Department of Molecular and Medical Pharmacology, and 5UCLA Molecular Biology Institute, Los Angeles, California; and 6Departments of Gynecologic Oncology and Cancer Biology, M.D. Anderson Comprehensive Cancer Center, Houston, Texas
-
- Benjamin F. Cox
- Authors' Affiliations: 1UCLA Norman Cousins Center at the Semel Institute for Neuroscience and Human Behavior, Department of Medicine, 2Division of Hematology-Oncology, UCLA School of Medicine, UCLA AIDS Institute, 3Jonsson Comprehensive Cancer Center, 4UCLA Department of Molecular and Medical Pharmacology, and 5UCLA Molecular Biology Institute, Los Angeles, California; and 6Departments of Gynecologic Oncology and Cancer Biology, M.D. Anderson Comprehensive Cancer Center, Houston, Texas
-
- Stephanie Yu
- Authors' Affiliations: 1UCLA Norman Cousins Center at the Semel Institute for Neuroscience and Human Behavior, Department of Medicine, 2Division of Hematology-Oncology, UCLA School of Medicine, UCLA AIDS Institute, 3Jonsson Comprehensive Cancer Center, 4UCLA Department of Molecular and Medical Pharmacology, and 5UCLA Molecular Biology Institute, Los Angeles, California; and 6Departments of Gynecologic Oncology and Cancer Biology, M.D. Anderson Comprehensive Cancer Center, Houston, Texas
-
- Matthew A. Pimentel
- Authors' Affiliations: 1UCLA Norman Cousins Center at the Semel Institute for Neuroscience and Human Behavior, Department of Medicine, 2Division of Hematology-Oncology, UCLA School of Medicine, UCLA AIDS Institute, 3Jonsson Comprehensive Cancer Center, 4UCLA Department of Molecular and Medical Pharmacology, and 5UCLA Molecular Biology Institute, Los Angeles, California; and 6Departments of Gynecologic Oncology and Cancer Biology, M.D. Anderson Comprehensive Cancer Center, Houston, Texas
-
- Veera Tangkanangnukul
- Authors' Affiliations: 1UCLA Norman Cousins Center at the Semel Institute for Neuroscience and Human Behavior, Department of Medicine, 2Division of Hematology-Oncology, UCLA School of Medicine, UCLA AIDS Institute, 3Jonsson Comprehensive Cancer Center, 4UCLA Department of Molecular and Medical Pharmacology, and 5UCLA Molecular Biology Institute, Los Angeles, California; and 6Departments of Gynecologic Oncology and Cancer Biology, M.D. Anderson Comprehensive Cancer Center, Houston, Texas
-
- Jesusa M.G. Arevalo
- Authors' Affiliations: 1UCLA Norman Cousins Center at the Semel Institute for Neuroscience and Human Behavior, Department of Medicine, 2Division of Hematology-Oncology, UCLA School of Medicine, UCLA AIDS Institute, 3Jonsson Comprehensive Cancer Center, 4UCLA Department of Molecular and Medical Pharmacology, and 5UCLA Molecular Biology Institute, Los Angeles, California; and 6Departments of Gynecologic Oncology and Cancer Biology, M.D. Anderson Comprehensive Cancer Center, Houston, Texas
-
- Kouki Morizono
- Authors' Affiliations: 1UCLA Norman Cousins Center at the Semel Institute for Neuroscience and Human Behavior, Department of Medicine, 2Division of Hematology-Oncology, UCLA School of Medicine, UCLA AIDS Institute, 3Jonsson Comprehensive Cancer Center, 4UCLA Department of Molecular and Medical Pharmacology, and 5UCLA Molecular Biology Institute, Los Angeles, California; and 6Departments of Gynecologic Oncology and Cancer Biology, M.D. Anderson Comprehensive Cancer Center, Houston, Texas
-
- Breanne D.W. Karanikolas
- Authors' Affiliations: 1UCLA Norman Cousins Center at the Semel Institute for Neuroscience and Human Behavior, Department of Medicine, 2Division of Hematology-Oncology, UCLA School of Medicine, UCLA AIDS Institute, 3Jonsson Comprehensive Cancer Center, 4UCLA Department of Molecular and Medical Pharmacology, and 5UCLA Molecular Biology Institute, Los Angeles, California; and 6Departments of Gynecologic Oncology and Cancer Biology, M.D. Anderson Comprehensive Cancer Center, Houston, Texas
-
- Lily Wu
- Authors' Affiliations: 1UCLA Norman Cousins Center at the Semel Institute for Neuroscience and Human Behavior, Department of Medicine, 2Division of Hematology-Oncology, UCLA School of Medicine, UCLA AIDS Institute, 3Jonsson Comprehensive Cancer Center, 4UCLA Department of Molecular and Medical Pharmacology, and 5UCLA Molecular Biology Institute, Los Angeles, California; and 6Departments of Gynecologic Oncology and Cancer Biology, M.D. Anderson Comprehensive Cancer Center, Houston, Texas
-
- Anil K. Sood
- Authors' Affiliations: 1UCLA Norman Cousins Center at the Semel Institute for Neuroscience and Human Behavior, Department of Medicine, 2Division of Hematology-Oncology, UCLA School of Medicine, UCLA AIDS Institute, 3Jonsson Comprehensive Cancer Center, 4UCLA Department of Molecular and Medical Pharmacology, and 5UCLA Molecular Biology Institute, Los Angeles, California; and 6Departments of Gynecologic Oncology and Cancer Biology, M.D. Anderson Comprehensive Cancer Center, Houston, Texas
-
- Steven W. Cole
- Authors' Affiliations: 1UCLA Norman Cousins Center at the Semel Institute for Neuroscience and Human Behavior, Department of Medicine, 2Division of Hematology-Oncology, UCLA School of Medicine, UCLA AIDS Institute, 3Jonsson Comprehensive Cancer Center, 4UCLA Department of Molecular and Medical Pharmacology, and 5UCLA Molecular Biology Institute, Los Angeles, California; and 6Departments of Gynecologic Oncology and Cancer Biology, M.D. Anderson Comprehensive Cancer Center, Houston, Texas
書誌事項
- 公開日
- 2010-09-14
- DOI
-
- 10.1158/0008-5472.can-10-0522
- 公開者
- American Association for Cancer Research (AACR)
この論文をさがす
説明
<jats:title>Abstract</jats:title> <jats:p>Metastasis to distant tissues is the chief driver of breast cancer–related mortality, but little is known about the systemic physiologic dynamics that regulate this process. To investigate the role of neuroendocrine activation in cancer progression, we used in vivo bioluminescence imaging to track the development of metastasis in an orthotopic mouse model of breast cancer. Stress-induced neuroendocrine activation had a negligible effect on growth of the primary tumor but induced a 30-fold increase in metastasis to distant tissues including the lymph nodes and lung. These effects were mediated by β-adrenergic signaling, which increased the infiltration of CD11b+F4/80+ macrophages into primary tumor parenchyma and thereby induced a prometastatic gene expression signature accompanied by indications of M2 macrophage differentiation. Pharmacologic activation of β-adrenergic signaling induced similar effects, and treatment of stressed animals with the β-antagonist propranolol reversed the stress-induced macrophage infiltration and inhibited tumor spread to distant tissues. The effects of stress on distant metastasis were also inhibited by in vivo macrophage suppression using the CSF-1 receptor kinase inhibitor GW2580. These findings identify activation of the sympathetic nervous system as a novel neural regulator of breast cancer metastasis and suggest new strategies for antimetastatic therapies that target the β-adrenergic induction of prometastatic gene expression in primary breast cancers. Cancer Res; 70(18); 7042–52. ©2010 AACR.</jats:p>
収録刊行物
-
- Cancer Research
-
Cancer Research 70 (18), 7042-7052, 2010-09-14
American Association for Cancer Research (AACR)
